ConductScience.org, home

Paper42972023PubMed

Early temporal transcriptional and cytokine responses distinguish chemotherapy sensitivity in patient-derived xenograft models of triple-negative breast cancer.

Rinkenbaugh AL and 10 others. Oncogene, 2026.

Cite this record

ConductScience Library. Early temporal transcriptional and cytokine responses distinguish chemotherapy sensitivity in patient-derived xenograft models of triple-negative breast cancer. Papers, record 42972023. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42972023

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Early temporal transcriptional and cytokine responses distinguish chemotherapy sensitivity in patient-derived xenograft models of triple-negative breast cancer.
Journal
Oncogene
Year
2026
Publication types
Journal Article
Revised in PubMed
2026-11-02

Source PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rinkenbaugh ALAmanda Lhttps://orcid.org/0000-0003-3276-6863
2Echeverria GVGloria Vhttps://orcid.org/0000-0002-3772-9298
3Shao JJiansu
4Qi YYuan
5Jeter-Jones SSabrina
6Zhang XXiaomei
7Cai SShirong
8Fu CChunxiao
9Symmans WFW Fraserhttps://orcid.org/0000-0002-1526-184X
10Chang JTJeffrey Thttps://orcid.org/0000-0002-4578-5636
11Piwnica-Worms HHelenhttps://orcid.org/0000-0003-4210-6738

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
RP160710Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas)PubMedPubMed
RR200009Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas)PubMedPubMed
RP160710Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas)PubMedPubMed
RP160710Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas)PubMedPubMed
P30CA016672U.S. Department of Health & Human Services | National Institutes of Health (NIH)P30CA016672PubMedNIH RePORTER

Download CSV of grants

References62

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
124882348Neoadjuvant therapy in the treatment of breast cancer.Surg Oncol Clin N Am2014https://conductscience.org/library/papers/24882348PubMed
232101663Pembrolizumab for Early Triple-Negative Breast Cancer.N Engl J Med2020https://conductscience.org/library/papers/32101663PubMed
335139274Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.N Engl J Med2022https://conductscience.org/library/papers/35139274PubMed
418250347Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.J Clin Oncol2008https://conductscience.org/library/papers/18250347PubMed
534902335Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.Lancet Oncol2022https://conductscience.org/library/papers/34902335PubMed
632966830
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Lancet2020https://conductscience.org/library/papers/32966830PubMed
721558518A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.JAMA2011https://conductscience.org/library/papers/21558518PubMed
821633166Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.J Clin Invest2011https://conductscience.org/library/papers/21633166PubMed
929378733Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification.Clin Cancer Res2018https://conductscience.org/library/papers/29378733PubMed
1033599688
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.
JAMA Oncol2021https://conductscience.org/library/papers/33599688PubMed
1122235097Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer.Clin Cancer Res2012https://conductscience.org/library/papers/22235097PubMed
1224356096Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.Cancer Discov2014https://conductscience.org/library/papers/24356096PubMed
1326021444Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response.Breast Cancer Res2015https://conductscience.org/library/papers/26021444PubMed
1429681456Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing.Cell2018https://conductscience.org/library/papers/29681456PubMed
1536001024Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer.Cancer Discov2022https://conductscience.org/library/papers/36001024PubMed
1622039576Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.Cancer Discov2011https://conductscience.org/library/papers/22039576PubMed
1726269531Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy.Cancer Res2015https://conductscience.org/library/papers/26269531PubMed
1827758887Tie2 Expression on Macrophages Is Required for Blood Vessel Reconstruction and Tumor Relapse after Chemotherapy.Cancer Res2016https://conductscience.org/library/papers/27758887PubMed
1928916656Chemotherapy-Induced Macrophage Infiltration into Tumors Enhances Nanographene-Based Photodynamic Therapy.Cancer Res2017https://conductscience.org/library/papers/28916656PubMed
2036727046The predictive value of neutrophil-to-lymphocyte ratio for overall survival and pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy.Front Oncol2022https://conductscience.org/library/papers/36727046PubMed

See all 62 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42972023

GET https://conductscience.org/api/papers/v1/42972023/references?page=2